TY - JOUR
T1 - Fluorescence polarization screening for allosteric small molecule ligands of the cholecystokinin receptor
AU - Harikumar, Kaleeckal G.
AU - Cawston, Erin E.
AU - Miller, Laurence J.
PY - 2011/8/1
Y1 - 2011/8/1
N2 - The success in screening for drug candidates is highly dependent on the power of the strategy implemented. In this work, we report and characterize a novel fluorescent benzodiazepine antagonist of the type 1 cholecystokinin receptor (3-(3-(7-fluoro-1-(2-isopropyl(4-methoxyphenyl)amino)-2-oxoethyl)-2,4- dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)ureido)benzoic acid) that can be used as a receptor ligand in a fluorescence polarization assay, which is ideally suited for the identification of small molecule allosteric modulators of this physiologically important receptor. By binding directly to the small molecule-docking region within the helical bundle of this receptor, this indicator can be displaced by many small molecule candidate drugs, even those that might not affect the binding of an orthosteric cholecystokinin-like peptide ligand. The biological, pharmacological, and fluorescence properties of this reagent are described, and proof-of-concept is provided in a fluorescence polarization assay utilizing this fluorescent benzodiazepine ligand.
AB - The success in screening for drug candidates is highly dependent on the power of the strategy implemented. In this work, we report and characterize a novel fluorescent benzodiazepine antagonist of the type 1 cholecystokinin receptor (3-(3-(7-fluoro-1-(2-isopropyl(4-methoxyphenyl)amino)-2-oxoethyl)-2,4- dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)ureido)benzoic acid) that can be used as a receptor ligand in a fluorescence polarization assay, which is ideally suited for the identification of small molecule allosteric modulators of this physiologically important receptor. By binding directly to the small molecule-docking region within the helical bundle of this receptor, this indicator can be displaced by many small molecule candidate drugs, even those that might not affect the binding of an orthosteric cholecystokinin-like peptide ligand. The biological, pharmacological, and fluorescence properties of this reagent are described, and proof-of-concept is provided in a fluorescence polarization assay utilizing this fluorescent benzodiazepine ligand.
UR - http://www.scopus.com/inward/record.url?scp=84860389960&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860389960&partnerID=8YFLogxK
U2 - 10.1089/adt.2010.0310
DO - 10.1089/adt.2010.0310
M3 - Article
C2 - 21395402
AN - SCOPUS:84860389960
SN - 1540-658X
VL - 9
SP - 394
EP - 402
JO - Assay and Drug Development Technologies
JF - Assay and Drug Development Technologies
IS - 4
ER -